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Oxysterols are oxidised derivatives of cholesterol or its precursors post lanosterol. They are in-
termediates in the biosynthesis of bile acids, steroid hormones and 1,25-dihydroxyvitamin D3.
Although often considered as metabolic intermediates there is a growing body of evidence that many
oxysterols are bioactive and their absence or excess may be part of the cause of a disease phenotype.
Using global lipidomics approaches oxysterols are underrepresented encouraging the development of
targeted approaches. In this article, we discuss recent discoveries important in oxysterol biochemistry
and some of the targeted lipidomic approaches used to make these discoveries.
© 2018 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
1. Introduction
Oxysterols came to prominence in the late 1970's with the
oxysterol hypothesis which proposed that the suppressive effect
of cholesterol on its own synthesis is mediated through oxy-
sterols not by cholesterol itself [1]. This has proved to be only
partly true, as cholesterol homeostasis in cells is modulated
through oxysterols, side-chain oxysterols inhibiting the SREBP2
(sterol regulatory element-binding protein 2) pathway and also
activating liver X receptors (LXRs) [2,3], although cholesterol it-
self is in fact the major regulator of its own synthesis through
binding to SCAP (SREBP cleavage activating protein) and pre-
venting transport of SERBP2 from the endoplasmic reticulum for
processing to its active form as a transcription factor for genes of
the cholesterol biosynthesis pathway [4]. In recent years oxy-
sterols have been shown to have important functions in immu-
nology [5e13], development [14,15] and cancer [16e20]. This has
stimulated wide-spread interest in their analysis using lip-
idomics technology [21,22]. Although mostly thought of as oxi-
dised forms of cholesterols, oxysterols can also be formed from
precursors of cholesterol greatly widening the range of molecules
required to be analysed in a lipidomic study.
2. Mass spectrometry-based technologies
Oxysterols tend not to be observed in global lipidomic analysis,
whether shot-gun based electrospray ionisation e mass spec-
trometry (ESI-MS) or liquid chromatography (LC)-MS based. This is
because of their comparatively low-abundance and poor ionisation
characteristics. However, methods have been developed for shot-
gun ESI e tandem MS (MS/MS) [23] and LC-MS/MS analysis
[21,22]. Gas chromatography (GC)-MS also provides an excellent
method for oxysterol and sterol analysis [24], but is less favoured in
lipidomics laboratories.
2.1. Targeted LC-MS/MS analysis
Russell and McDonald and co-workers [21,22] have developed
LC-MS/MS lipidomics protocols for oxysterol analysis based on the
classical sample preparation method of Dzeletovic et al. [24] and
multiple reaction monitoring (MRM) using a triple quadrupole
mass spectrometer exploiting [M þ NH4]þ adducts for fragmenta-
tion. They have made the largest study to date in terms of sample
numbers, analysing 3230 serum samples for 60 sterols [22]. The
McDonald and Russell method is the template on which many
other LC-MS/MS studies have been made [25]. An inherent
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drawback, however, of targeted approaches is that only targeted
oxysterol are detected and unexpected ones are missed.
2.2. LC-MS/MS with derivatisation
The concept of targeted oxysterol analysis has been extended
with the use of derivatisation methods to enhance sensitivity.
Derivatisation of hydroxy groups to dimethylglycine or N,N-
dimethylaminobutyrate esters has recently gained popularity for
the diagnosis of Niemann Pick (NP) type B and C disease where
7-oxocholesterol (7-OC) and cholestane-3b,5a,6b-triol (3b,5a,6b-
triol, see Supplementary Table for a list of common and sys-
tematic names and abbreviations and Supplementary Figures 1 &
2 for structures) are elevated in plasma of NP patients [26,27],
while derivatisation to picolinate esters has proved successful for
analysis of both sterols and oxysterols [28]. “Primary” oxystrols
have a 3b-hydroxy group, however, once 7a-hydroxylated, the
3b-hydroxy-5-ene function can be oxidised to a 3-oxo-4-ene by
the enzyme hydroxysteroid dehydrogenase (HSD) 3B7
(Supplementary Figure 1). The 3-oxo group is readily derivatised
by hydrazine reagents, e.g. quaternary nitrogen containing Girard
hydrazines, (hydrazinocarbonylmethyl)trimethylammonium
chloride, GT or 1-(hydrazinocarbonylmethyl)pyridinium chloride,
GP [29], or hydroxylamine reagents, e.g. O-(3-
trimethylammoniumpropyl) hydroxylamine bromide [30], to
enhance sensitivity during plasma analysis, valuable for the
identiﬁcation of patients with inborn errors of metabolism. The
3b-hydroxy-5-ene function found in “primary” oxysterols can be
oxidised ex vivo by bacterial cholesterol oxidase to the 3-oxo-4-
ene function [31], this has been exploited with subsequent Gir-
ard derivatisation, using GP or GT, in numerous studies to
enhance the sensitivity of oxysterol analysis [8,10,19,32e34].
Despite advantages, derivatisation technology is often criticised
for being laborious and difﬁcult to automate.
3. Lipidomics and oxysterol biochemistry
3.1. Cholesterol 25-hydroxylase, 25-hydroxycholesterol and the
immune system
Cholesterol 25-hydroxylase (CH25H in man and Ch25h in
mouse) is the enzyme which oxidises cholesterol to 25-
hydroxycholesterol (25-HC) (Supplementary Figure 1). CH25H is
not a cytochrome P450 (CYP), but a member of a family of enzymes
that utilize diiron cofactors to catalyse hydroxylation. Some CYP
enzymes also have some 25-hydroxylase activity, but often sec-
ondary to their main catalytic functions [35]. In a major LC-MS
lipidomic study investigating the effect of Kdo2-lipid A, the active
component of an inﬂammatory lipopolysaccharide (LPS), on the
mouse macrophage cell line RAW264.7, Dennis et al. found 25-HC
to be elevated in abundance, correlating with a 4-fold increase in
Ch25hmRNA [36]. The mRNA increase was 15-fold in bone marrow
derivedmacrophages. In a parallel study, Bauman et al. showed that
stimulation of macrophage Toll-like receptor 4 (TLR4) induced
Ch25h expression and 25-HC synthesis and that 25-HC suppressed
interleukin-2 (IL-2) mediated stimulation of B-cell proliferation,
repressed activation induced cytidine deaminase (AID) expression,
and blocked class switch recombination, leading to markedly
decreased IgA production [5] (Fig. 1). Suppression of IgA class
switching in B cells in response to TLR activation provides a
mechanism for local and systemic negative regulation of the
adaptive immune response by the innate immune system [5].
Ch25h is an interferon (IFN) regulated gene and upon viral infec-
tion, or IFN-stimulation, 25-HC is synthesised by macrophages and
acts as a potent paracrine inhibitor of viral infection demonstrating
a role in the innate immune pathway [8].
Reboldi et al. have shown that activated macrophages from
the Ch25h/- mouse overproduce inﬂammatory IL-1 family cy-
tokines [9]. They proposed that 25-HC represses Il1b transcrip-
tion and repressed IL-1 activating inﬂammasomes by repressing
the SREBP2 pathway [9]. Reboldi et al. also found that Ch25h/-
mice exhibited increased sensitivity to septic shock, exacerbated
experimental autoimmune encephalomyelitis (EAE), a mouse
model for multiple sclerosis, and a stronger ability to repress
bacterial growth. They concluded that 25-HC is a mediator in the
negative feedback pathway of IFN-signalling on IL1-family cyto-
kine production and inﬂammasome activity. In agreement with
the multiple sclerosis mouse model, Crick et al. in a LC-MS based
sterolomic study exploiting GP-derivatisation found reduced
plasma levels of 25-HC in plasma of multiple sclerosis patients
[34].
Further understanding of the role of 25-HC in the inﬂammatory
system comes from thework of Dang et al. [12], who conﬁrmed that
type 1 IFN restrains 1L-1b driven inﬂammation in macrophages by
up-regulating Ch25h and 25-HC and repressing SREBP2 driven
cholesterol synthesis. In the absence of Ch25h, cholesterol overload
triggers mitochondrial DNA release and activation of AIM2 (absent
inmelanoma 2) inﬂammasomes in activatedmacrophages [12]. The
inﬂammasome promotes the maturation of the inﬂammatory cy-
tokines e.g. IL-1b by recruitment and activation of caspase-1 that
processes IL-1b into its active form. Consequently, in Ch25h/-
macrophages there is an exaggerated response to pathogen derived
activators.
There is just one report of CH25H deﬁciency in man. Goenka
et al. reported on ﬁve unrelated infants born to consanguineous
parents showing homozygous deletions of CH25H and the adjacent
gene LIPA (lipase A, lysosomal acid type) in all ﬁve children [37].
LIPA encodes the enzyme lysosomal acid lipase, deﬁciency in which
leads to Wolman disease in infants, a lysosomal storage disease
characterised by accumulation of cholesterol esters. Neonatal BCG
(Bacillus CalmetteeGuerin) vaccination against Mycobacterium
tuberculosis infection was performed on four of the children and in
three local BCG abscesses developed. Otherwise, none of the chil-
dren had any other history of prolonged, unusual or recurrent in-
fections [37]. It is tempting to speculate that the absence of
macrophage derived 25-HC leads to an exaggerated response to the
BCG vaccination and abscess.
In contrast to the ﬁndings of Reboldi et al. [9], Chalmin et al.
found that deletion of Ch25h (Ch25h/) attenuated EAE [11],
limiting the trafﬁcking of CD4þ T cells to the central nervous
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Fig. 1. Schematic representation of the regulation of immune responses by 25-HC and
7a,25-diHC.
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system. Chamlin et al. explained this by proposing that 7a,25-
dihydroxycholesterol (7a,25-diHC), a downstream metabolite of
25-HC, promotes themigration of activated proinﬂammatory Tcells
up a gradient of 7a,25-diHC by binding to the G protein-coupled
receptor (GPCR) Epstein-Barr virus-induced gene 2 (EBI2, GPR183,
Fig. 1) [11].
3.2. EBI2 and 7a,25-diHC in immunity
EBI2 regulates the positioning of immune cells in secondary
lymphoid organs (sites of lymphocyte activation by antigens) and
polymorphisms in the receptor have been associated with inﬂam-
matory autoimmune diseases. Hannedouche et al. puriﬁed the
ligand for EBI2 by exploiting a bioactivity assay and sheep sepsis
model [7]. By high resolution ESI-MS the ligand was identiﬁed as a
cholestentriol. Following further puriﬁcation and NMR analysis, the
ligand was identiﬁed as 7a,25-diHC. In a study published at the
same time, Liu et al. conﬁrmed the EBI2 ligand as 7a,25-diHC [6].
The positional isomer 7a,(25R)26-dihydroxycholesterol (7a,26-
diHC) was shown to have similar activation capacity towards EBI2
and both isomers act as chemoattractants for immune cells
expressing EBI2 [7].
7a,25-diHC can be synthesised by multiple metabolic pathway
(Supplementary Figure 1). One route is via 25-hydroxylation of
cholesterol by CH25H followed by 7a-hydroxylation by CYP7B1.
CYP3A enzymes also have sterol 25-hydroxylation activity as do
CYP27A1 and CYP46A1 [35]. 7a,25-diHC can alternatively be
formed via 7a-hydroxylation of cholesterol by CYP7A1 followed
by 25-hydroxylation of 7a-hydroxycholesterol (7a-HC) to give
7a,25-diHC. By whatever route it may be formed 7a,25-diHC is
inactivated by HSD3B7. In Ch25h/mice 7a,25-diHC was found to
be at, or below, the detection limit in spleen and lymph node
tissue extracts, but in wildtype mice was clearly detectable
following LPS challenge indicating that 7a,25-diHC is generated in
the spleen in a CH25H-dependent manner [7]. Interestingly,
Hannedouche at al found that similar to EBI2/ mice, Ch25h/
mice fail to position activated B cells within the spleen to the outer
follicle and mount a reduced plasma cell response after an im-
mune challenge [7]. This supports the hypothesis that 7a,25-diHC
is generated in a CH25H dependent manner and has a proin-
ﬂammatory function.
In a recent study, Wanke et al. conﬁrmed that EBI2 in combi-
nation with 7a,25-diHC direct immune cell localisation in second-
ary lymphoid organs [13]. They found that EBI2 is expressed by
Th17 cells in inﬂammation and that EBI2 promotes early CNS
inﬁltration in passive EAE [13]. In a targeted lipidomic study for
oxysterols they found, using LC-MS/MS methodology [25], that not
only 25-HC and 7a,25-diHC were of enhanced abundance in spinal
cord of mice with EAE, but also 7a,26-diHC and 7a,24-
dihydroxycholesterol (7a,24-diHC), although 24-
hydroxycholesterol (24-HC) and 26-hydroxycholesterol (26-HC)
were less abundant than in naïve mice [13]. In EAE mice expression
of both Ch25h and Cyp7b1 were up-regulated, but Hsd3b7 was
reduced. Interestingly, microglia were found to express Ch25h
during EAE, while Cyp7b1 was expressed in inﬁltrating lympho-
cytes and monocytes. Hsd3b7 was expressed by both cellular pop-
ulations. Ch25h was not expressed in microglia from the healthy
CNS [13].
In summary, there is conﬂicting evidence regarding the role of
CH25H and 25-HC in autoimmunity. Data from Reboldi et al. sug-
gests that Ch25h/mice experience exacerbated EAE [9] and Dang
et al. have shown that 1L-1b driven inﬂammation in macrophages
is restrained by up-regulating Ch25h and 25-HC [12]. On the other
hand, Chalmin et al. found that deletion of Ch25h attenuated EAE
[11], while Wanke et al. found that Ch25h and Cyp7b1 were up-
regulated in the CNS of EAE mice [13].
3.3. Oxysterols and hedgehog signalling
The hedgehog (Hh) signalling pathway is essential for animal
development. It provides a communication system between cells of
adult and of developing tissue and regulates cell proliferation, stem
cell maintenance and fate speciﬁcation. Hh signalling can be mis-
activated to cause cancer.
The phenotype of congenital Hh deﬁciency is similar to that
found in some inborn errors of cholesterol biosynthesis e.g.
lathosterolosis, desmosterolosis and Smith-Lemli-Opitz syn-
drome (SLOS), where cholesterol biosynthesis is reduced and
its precursors, lathosterol, desmosterol and 7-
dehydrocholesterol (7-DHC) accumulate in the respective dis-
eases (Supplementary Figure 2) [38]. Three protein families are
critically involved in Hh signalling. Of these, the Hh ligands,
sonic hedgehog (SHH), indian hedgehog (IHH) and desert
hedgehog (DHH), are modiﬁed with cholesterol at the C-ter-
minus. In vertebrates SHH is the most well studied and is
secreted into the extracellular space where it binds to the
membrane associated protein Patched 1 (PTCH1). PTCH1 indi-
rectly inhibits transport of the GPCR Smoothened (SMO), a 7-
transmembrane domain (TMD) protein with an extracellular
cysteine rich domain (CRD), to primary cilium, antenna that
project from the surface of most cells. When SHH binds to
PTCH1 repression of SMO is relieved and SMO enters the
cilium where a second activation step initiates down-stream
signalling through GLI1 transcription factors which regulate
developmental patterning (Fig. 2) [39]. Inhibition of SMO by
PTCH1 can be overcome by cholesterol and oxysterols in the
absence of SHH. Cholesterol has been found to be not just
necessary but also sufﬁcient to activate signalling by the Hh
pathway, binding to SMO at its CRD [40,41], the same binding
site as some oxysterols. Two oxysterols of elevated abundance
in SLOS and derived from 7-DHC [42], (25R)26-hydroxy-7-
oxocholesterol (26H,7O-C) and 25-hydroxy-7-oxocholesterol
(25H,7-OC) have been found to activate the Hh signalling
pathway via binding to the CRD of SMO [14], while the
downstream metabolite of 26H,7O-C, 3b-hydroxy-7-oxoxholest-
5-en-(25R)26-oic acid (3bH,7O-CA, Supplementary Figure S2)
inhibits Hh signalling in the presence of SHH ligand, again by
binding to the CRD of SMO [42]. SLOS, which results from 7-
dehydrocholesterol reductase (DHCR7) deﬁciency, phenocopies
Hh deﬁciency, and we speculate that dysmorphology observed
in SLOS is a consequence of dysregulated Hh signalling.
Another oxysterol, 3b,5a-dihydroxycholest-7-en-6-one
(DHCEO), like 25H,7O-C, 26H,7O-C and 3bH,7O-CA, derived
from 7-DHC, also inhibits Hh signalling by binding to SMO, but
at a site distinct from other oxysterols [15]. Unlike, 25H,7-OC,
PTCH1 SMO
GlI1
SHH 26H,7OC Cholesterol3βH,7O-CA
DHCEO
SMO
Fig. 2. Schematic representation of the role of oxysterols in the Hh signalling pathway.
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26H,7-OC and 3bH,7O-CA which are formed enzymatically from
7-DHC, DHCEO is formed from 7-DHC via free radical reactions.
3.4. Oxysterols and cancer
Recent studies have uncovered important links between oxy-
sterols and breast cancer. Dendgrogenin A (DDA), a histamine
conjugate of 5a,6-epoxycholesterol (5a,6-EC, Supplementary
Figure 1), was ﬁrst identiﬁed in mouse brain tissue by LC com-
bined with off-line MS and MS with multistage fragmentation
(MSn) and comparison to an authentic standard [18]. DDA was not
detected in cancer cell lines and was less abundant in human breast
tumours compared to normal tissue. DDA triggered tumour re-
differentiation and growth control in mice, improving animal sur-
vival [18]. The precursor of DDA, 5a,6-EC, and its isomer 5b,6-EC,
can alternatively be converted enzymatically by cholesterol exp-
oxide hydrolase (ChEH) to 3b,5a,6b-triol. DDA is an inhibitor of
ChEH, which itself is a heterodimer of two enzymes of the
cholesterol biosynthesis pathway, DHCR7 and 3b-hydroxysteroid-
D-8,7-sterol isomerase (D8D7I, Fig. 3) [18]. 3b,5a,6b-triol can be
metabolised to the bile acid 3b,5a,6b-trihydroxycholanoic acid
(3b,5a,6b-triHBA) [43,44] through metabolism by CYP27A1 fol-
lowed by side-chain shortening by peroxisomal enzymes, or alter-
natively be oxidised at C-6 to 3b,5a-dihydroxycholestan-6-one
(3b,5a-diHC-6O) by HSD11B2 [20]. 3b,5a-diHC-6O was found to
stimulate breast cancer cell proliferation both in vivo and in vitro in
estrogen receptor positive (ERþ) and ER negative (ER-) cells and
tissues [20]. In a targeted analysis utilising LC separation off line
with chemical ionisation -MS 3b,5a-diHC-6O was identiﬁed in
breast cancer tissue at higher levels than in adjacent normal tissue.
Interestingly, breast cancer samples showed greater expression of
the two enzymes required for 3b,5a-diHC-6O formation from 5,6-
EC, i.e. ChEH and HSD11B2, than normal tissue and in analysis of
breast cancer mRNA databases, overexpression of HSD11B2 and
ChEH correlated with a higher risk of patient death [20]. 3b,5a-
diHC-6O was found to be a ligand to the glucocorticoid receptor
(GR), and high expression of the GR correlates with poor thera-
peutic response or prognosis in many solid tumours [20]. 5a,6-EC,
the precursor of DDA, along with its isomer 5b,6-EC sit at the
fulcrum of tumour progression. Conjugation with histamine by an
enzyme still to be identiﬁed will lead to the tumour suppressor
DDA, alternatively, hydrolysis by ChEH to 3b,5a,6b-triol then
oxidation by HSD11B2 will lead to the oncometabolite 3b,5a-diHC-
6O. Metabolism of 3b,5a,6b-triol to 3b,5a-diHC-6O can be diverted
by CYP27A1 oxidation to cholestane-3b,5a,6b, (25R)26-tetrol
(3b,5a,6b,26-tetrol) and ultimately to the bile acid 3b,5a,6b-
triHBA. In this case expression of CYP27A1 in breast cancer tissue
would lead to the deactivation of 3b,5a,6b-triol, however, it should
be noted that the biological activity of 3b,5a,6b,26-tetrol and its
metabolites have yet to be explored.
A link between breast cancer and CYP27A1, in this case to
generate an oncogenic metabolite, 26-HC, (also known as 27-
hydroxycholesterol) was established by two group, Wu et al.
[16] and Nelson et al. [17], who published their data almost
simultaneously. 26-HC is a known selective estrogen receptor
modulator (SERM), and using the LC-MS/MS method of McDonald
et al. [21], Wu et al. showed that the tumour content of 26-HC was
elevated compared to normal tissue from ER þ breast cancer pa-
tients and that normal tissue from these patients had a higher
content of 26-HC than tissue from controls [16]. 26-HC was shown
to stimulate MCF-7 cell xenograft growth in mice [16]. Integration
by Wu et al. of the Cancer Genome Atlas found that CYP27A1
expression was similar in normal breast and ER þ tumours but
CYP7B1 expression was decreased by 50% in ER þ tumours
compared with normal breast tissue [16]. CYP7B1 is the oxysterol
7a-hydroxylase that metabolises 26-HC to 7a,26-diHC. Interest-
ingly, serum analysis of women with ER þ breast cancer and
cancer free subjects showed that at presentation the mean 26-HC
ER+
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Fig. 3. Schematic representation of the involvement of oxysterols in cancer.
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levels were not signiﬁcantly different between the two groups,
indicating that local metabolism must account for elevated 26-HC
in breast cancer tissue.
Nelson et al. also showed that 26-HC was increased in
ER þ mouse models of breast cancer and that in human breast
cancer tissue CYP27A1 protein expression correlated with tumour
grade, increased expression of this enzyme was observed in higher
grade tumours [17]. This study also demonstrated LXR-dependent
metastasis in mouse models of breast cancer; signiﬁcantly 26-HC
is a ligand to LXR [17].
While tamoxifen, a SERM, which also binds to and inhibits
ChEH, is prescribed to both pre- and post-menopausal women
with ER þ breast cancer, aromatase inhibitors are used to treat
postmenopausal women with ER þ breast cancer. Despite endo-
crine therapy, many patients relapse because of adaptive changes
associated with resistance to aromatase inhibitors. Long-term es-
trogen deprivation (LTED) of ER þ cell lines provide a model of
relapse to aromatase inhibitors and Simigdala et al. have shown
using proteomic and transcriptomic analysis that the cholesterol
biosynthesis pathway is upregulated in ER þ LTED but not ER-
LTED cell lines [19]. Interestingly, in light of the study by Voisin
et al. [20], D8D7I was particularly upregulated in proteomic
analysis of the ER þ breast cancer cell line MCF7 LTED cells. Using
LC-MS/MS with GT derivatisation Simigdala et al. showed a sig-
niﬁcant increase in the concentration of 25-HC but not 26-HC in
MCF7 LTED cells compared to the parental cell line [19]. Like, 26-
HC, 25-HC increased ER mediated transcription of ER regulated
genes in MCF7 LTED but not ER- LTED cells. In terms of absolute
cell number, addition of 25-HC or 26-HC to MCF7 LTED cells
resulted in a small but signiﬁcant increase. In addition, the anti-
proliferative effect of fulvestrant, a selective estrogen receptor
degrader, in MCF7 LTED cells was reduced by addition of 25-HC or
26-HC [19]. In summary, this data indicates that 25-HC, like 26-HC,
a SERM, plays a role in the resistance of ER þ breast cancer to
aromatase therapy.
Although the serum concentration of 26-HC does not appear to
differ between ER þ breast cancer patients and controls, the pos-
sibility exists that evidence for an increased local production be-
comes lost by analysing the bulk medium. Exosomes are
extracellular vesicles released by exocytosis, they are rich in lipids
and are released by cancer cells in greater numbers than by healthy
cells. This led Roberg-Larsen et al. to investigate using capillary LCe
MS/MS with GT derivatisation the oxysterol content of exosomes.
They found increased 26-HC in exosomes from ER þ MCF7 cells
compared to ER- breast cancer cell lines or other non-cancer cell
lines. They concluded that oxysterol proﬁling of cancer cells may
have diagnostic value [33].
In summary, recent studies have revealed the importance of
oxysterols in health and disease. While 25-HC generated by
CH25H in macrophages appears to have an anti-inﬂammatory
function, its CYP7B1 metabolite 7a,25-diHC appears to be pro-
inﬂammatory. CYP27A1 metabolises cholesterol to the
ER þ breast cancer oncometabolite 26-HC, but CYP27A1 also
provides a deactivation rout for 3b,5a,6b-triol diverting its meta-
bolism from the oncometabolite 3b,5a-diHC-6O to bile acid
biosynthesis. CYP27A1 is also critical for production of the Hh
pathway activator 26H,7O-C and inhibitor 3bH,7O-CA. In healthy
tissue the production and removal of oxysterols is exquisitely
regulated. Dysregulation may lead to disease.
Acknowledgement
This work was supported by the UK Biotechnology and Biolog-
ical Sciences Research Council (BBSRC, grant numbers BB/I001735/1
and BB/N015932/1 to WJG, BB/L001942/1 to YW).
Appendix A. Supplementary data
Supplementary data related to this article can be found at
https://doi.org/10.1016/j.bbrc.2018.02.019.
References
[1] A.A. Kandutsch, H.W. Chen, H.J. Heiniger, Biological activity of some oxygen-
ated sterols, Science 201 (1978) 498e501.
[2] A. Radhakrishnan, Y. Ikeda, H.J. Kwon, M.S. Brown, J.L. Goldstein, Sterol-
regulated transport of SREBPs from endoplasmic reticulum to Golgi: oxy-
sterols block transport by binding to Insig, Proc. Natl. Acad. Sci. U. S. A. 104
(2007) 6511e6518.
[3] J.M. Lehmann, S.A. Kliewer, L.B. Moore, T.A. Smith-Oliver, B.B. Oliver, J.L. Su,
S.S. Sundseth, D.A. Winegar, D.E. Blanchard, T.A. Spencer, T.M. Willson, Acti-
vation of the nuclear receptor LXR by oxysterols deﬁnes a new hormone
response pathway, J. Biol. Chem. 272 (1997) 3137e3140.
[4] M.S. Brown, A. Radhakrishnan, J.L. Goldstein, Retrospective on cholesterol
homeostasis: the central role of scap, Annu. Rev. Biochem. (2017), https://
doi.org/10.1146/annurev-biochem-062917-011852. Ahead of print.
[5] D.R. Bauman, A.D. Bitmansour, J.G. McDonald, B.M. Thompson, G. Liang,
D.W. Russell, 25-Hydroxycholesterol secreted by macrophages in response to
Toll-like receptor activation suppresses immunoglobulin A production, Proc.
Natl. Acad. Sci. U. S. A. 106 (2009) 16764e16769.
[6] C. Liu, X.V. Yang, J. Wu, C. Kuei, N.S. Mani, L. Zhang, J. Yu, S.W. Sutton, N. Qin,
H. Banie, L. Karlsson, S. Sun, T.W. Lovenberg, Oxysterols direct B-cell migration
through EBI2, Nature 475 (2011) 519e523.
[7] S. Hannedouche, J. Zhang, T. Yi, W. Shen, D. Nguyen, J.P. Pereira, D. Guerini,
B.U. Baumgarten, S. Roggo, B. Wen, R. Knochenmuss, S. Noel, F. Gessier,
L.M. Kelly, M. Vanek, S. Laurent, I. Preuss, C. Miault, I. Christen, R. Karuna,
W. Li, D.I. Koo, T. Suply, C. Schmedt, E.C. Peters, R. Falchetto, A. Katopodis,
C. Spanka, M.O. Roy, M. Detheux, Y.A. Chen, P.G. Schultz, C.Y. Cho, K. Seuwen,
J.G. Cyster, A.W. Sailer, Oxysterols direct immune cell migration via EBI2,
Nature 475 (2011) 524e527.
[8] M. Blanc, W.Y. Hsieh, K.A. Robertson, K.A. Kropp, T. Forster, G. Shui, P. Lacaze,
S. Watterson, S.J. Grifﬁths, N.J. Spann, A. Meljon, S. Talbot, K. Krishnan,
D.F. Covey, M.R. Wenk, M. Craigon, Z. Ruzsics, J. Haas, A. Angulo, W.J. Grifﬁths,
C.K. Glass, Y. Wang, P. Ghazal, The transcription factor STAT-1 couples
macrophage synthesis of 25-hydroxycholesterol to the interferon antiviral
response, Immunity 38 (2013) 106e118.
[9] A. Reboldi, E.V. Dang, J.G. McDonald, G. Liang, D.W. Russell, J.G. Cyster,
Inﬂammation. 25-Hydroxycholesterol suppresses interleukin-1-driven
inﬂammation downstream of type I interferon, Science 345 (2014) 679e684.
[10] P. Soroosh, J. Wu, X. Xue, J. Song, S.W. Sutton, M. Sablad, J. Yu, M.I. Nelen,
X. Liu, G. Castro, R. Luna, S. Crawford, H. Banie, R.A. Dandridge, X. Deng,
A. Bittner, C. Kuei, M. Tootoonchi, N. Rozenkrants, K. Herman, J. Gao, X.V. Yang,
K. Sachen, K. Ngo, W.P. Fung-Leung, S. Nguyen, A. de Leon-Tabaldo, J. Blevitt,
Y. Zhang, M.D. Cummings, T. Rao, N.S. Mani, C. Liu, M. McKinnon, M.E. Milla,
A.M. Fourie, S. Sun, Oxysterols are agonist ligands of RORgammat and drive
Th17 cell differentiation, Proc. Natl. Acad. Sci. U. S. A. 111 (2014)
12163e12168.
[11] F. Chalmin, V. Rochemont, C. Lippens, A. Clottu, A.W. Sailer, D. Merkler,
S. Hugues, C. Pot, Oxysterols regulate encephalitogenic CD4(þ) T cell traf-
ﬁcking during central nervous system autoimmunity, J. Autoimmun. 56
(2015) 45e55.
[12] E.V. Dang, J.G. McDonald, D.W. Russell, J.G. Cyster, Oxysterol restraint of
cholesterol synthesis prevents AIM2 inﬂammasome activation, Cell 171
(2017) 1057e1071 e1011.
[13] F. Wanke, S. Moos, A.L. Croxford, A.P. Heinen, S. Graf, B. Kalt, D. Tischner,
J. Zhang, I. Christen, J. Bruttger, N. Yogev, Y. Tang, M. Zayoud, N. Israel,
K. Karram, S. Reissig, S.M. Lacher, C. Reichhold, I.A. Mufazalov, A. Ben-Nun,
T. Kuhlmann, N. Wettschureck, A.W. Sailer, K. Rajewsky, S. Casola,
A. Waisman, F.C. Kurschus, EBI2 is highly expressed in multiple sclerosis le-
sions and promotes early CNS migration of encephalitogenic CD4 T cells, Cell
Rep. 18 (2017) 1270e1284.
[14] B.R. Myers, N. Sever, Y.C. Chong, J. Kim, J.D. Belani, S. Rychnovsky, J.F. Bazan,
P.A. Beachy, Hedgehog pathway modulation by multiple lipid binding sites on
the smoothened effector of signal response, Dev. Cell 26 (2013) 346e357.
[15] N. Sever, R.K. Mann, L. Xu, W.J. Snell, C.I. Hernandez-Lara, N.A. Porter,
P.A. Beachy, Endogenous B-ring oxysterols inhibit the Hedgehog component
Smoothened in a manner distinct from cyclopamine or side-chain oxysterols,
Proc. Natl. Acad. Sci. U. S. A. 113 (2016) 5904e5909.
[16] Q. Wu, T. Ishikawa, R. Sirianni, H. Tang, J.G. McDonald, I.S. Yuhanna,
B. Thompson, L. Girard, C. Mineo, R.A. Brekken, M. Umetani, D.M. Euhus, Y. Xie,
P.W. Shaul, 27-Hydroxycholesterol promotes cell-autonomous, ER-positive
breast cancer growth, Cell Rep. 5 (2013) 637e645.
[17] E.R. Nelson, S.E. Wardell, J.S. Jasper, S. Park, S. Suchindran, M.K. Howe,
N.J. Carver, R.V. Pillai, P.M. Sullivan, V. Sondhi, M. Umetani, J. Geradts,
D.P. McDonnell, 27-Hydroxycholesterol links hypercholesterolemia and
breast cancer pathophysiology, Science 342 (2013) 1094e1098.
[18] P. de Medina, M.R. Paillasse, G. Segala, M. Voisin, L. Mhamdi, F. Dalenc,
M. Lacroix-Triki, T. Filleron, F. Pont, T.A. Saati, C. Morisseau, B.D. Hammock,
S. Silvente-Poirot, M. Poirot, Dendrogenin A arises from cholesterol and
W.J. Grifﬁths, Y. Wang / Biochemical and Biophysical Research Communications xxx (2018) 1e6 5
Please cite this article in press as: W.J. Grifﬁths, Y. Wang, An update on oxysterol biochemistry: New discoveries in lipidomics, Biochemical and
Biophysical Research Communications (2018), https://doi.org/10.1016/j.bbrc.2018.02.019
histamine metabolism and shows cell differentiation and anti-tumour prop-
erties, Nat. Commun. 4 (2013) 1840.
[19] N. Simigdala, Q. Gao, S. Pancholi, H. Roberg-Larsen, M. Zvelebil, R. Ribas,
E. Folkerd, A. Thompson, A. Bhamra, M. Dowsett, L.A. Martin, Cholesterol
biosynthesis pathway as a novel mechanism of resistance to estrogen depri-
vation in estrogen receptor-positive breast cancer, Breast Cancer Res. 18
(2016) 58.
[20] M. Voisin, P. de Medina, A. Mallinger, F. Dalenc, E. Huc-Claustre, J. Leignadier,
N. Serhan, R. Soules, G. Segala, A. Mougel, E. Noguer, L. Mhamdi, E. Bacquie,
L. Iuliano, C. Zerbinati, M. Lacroix-Triki, L. Chaltiel, T. Filleron, V. Cavailles, T. Al
Saati, P. Rochaix, R. Duprez-Paumier, C. Franchet, L. Ligat, F. Lopez, M. Record,
M. Poirot, S. Silvente-Poirot, Identiﬁcation of a tumor-promoter cholesterol
metabolite in human breast cancers acting through the glucocorticoid re-
ceptor, Proc. Natl. Acad. Sci. U. S. A. 114 (2017) E9346eE9355.
[21] J.G. McDonald, D.D. Smith, A.R. Stiles, D.W. Russell, A comprehensive method
for extraction and quantitative analysis of sterols and secosteroids from hu-
man plasma, J. Lipid Res. 53 (2012) 1399e1409.
[22] A.R. Stiles, J. Kozlitina, B.M. Thompson, J.G. McDonald, K.S. King, D.W. Russell,
Genetic, anatomic, and clinical determinants of human serum sterol and
vitamin D levels, Proc. Natl. Acad. Sci. U. S. A. 111 (2014) E4006eE4014.
[23] X. Jiang, D.S. Ory, X. Han, Characterization of oxysterols by electrospray
ionization tandem mass spectrometry after one-step derivatization with
dimethylglycine, Rapid Commun. Mass Spectrom. 21 (2007) 141e152.
[24] S. Dzeletovic, O. Breuer, E. Lund, U. Diczfalusy, Determination of cholesterol
oxidation products in human plasma by isotope dilution-mass spectrometry,
Anal. Biochem. 225 (1995) 73e80.
[25] R. Karuna, I. Christen, A.W. Sailer, F. Bitsch, J. Zhang, Detection of dihydrox-
ycholesterols in human plasma using HPLC-ESI-MS/MS, Steroids 99 (2015)
131e138.
[26] X. Jiang, R. Sidhu, F.D. Porter, N.M. Yanjanin, A.O. Speak, D.T. te Vruchte,
F.M. Platt, H. Fujiwara, D.E. Scherrer, J. Zhang, D.J. Dietzen, J.E. Schaffer,
D.S. Ory, A sensitive and speciﬁc LC-MS/MS method for rapid diagnosis of
Niemann-Pick C1 disease from human plasma, J. Lipid Res. 52 (2011)
1435e1445.
[27] S. Boenzi, F. Deodato, R. Taurisano, D. Martinelli, D. Verrigni, R. Carrozzo,
E. Bertini, A. Pastore, C. Dionisi-Vici, D.W. Johnson, A new simple and rapid LC-
ESI-MS/MS method for quantiﬁcation of plasma oxysterols as dimethylami-
nobutyrate esters. Its successful use for the diagnosis of Niemann-Pick type C
disease, Clin. Chim. Acta 437 (2014) 93e100.
[28] A. Honda, K. Yamashita, T. Hara, T. Ikegami, T. Miyazaki, M. Shirai, G. Xu,
M. Numazawa, Y. Matsuzaki, Highly sensitive quantiﬁcation of key regulatory
oxysterols in biological samples by LC-ESI-MS/MS, J. Lipid Res. 50 (2009)
350e357.
[29] A.E. DeBarber, Y. Sandlers, A.S. Pappu, L.S. Merkens, P.B. Duell, S.R. Lear,
S.K. Erickson, R.D. Steiner, Proﬁling sterols in cerebrotendinous xanthoma-
tosis: utility of Girard derivatization and high resolution exact mass LC-ESI-
MS(n) analysis, J Chromatogr B Analyt Technol Biomed Life Sci 879 (2011)
1384e1392.
[30] A.E. DeBarber, J. Luo, R. Giugliani, C.F. Souza, J.P. Chiang, L.S. Merkens,
A.S. Pappu, R.D. Steiner, A useful multi-analyte blood test for cere-
brotendinous xanthomatosis, Clin. Biochem. 47 (2014) 860e863.
[31] J. MacLachlan, A.T. Wotherspoon, R.O. Ansell, C.J. Brooks, Cholesterol oxidase:
sources, physical properties and analytical applications, J. Steroid Biochem.
Mol. Biol. 72 (2000) 169e195.
[32] P.J. Crick, T. William Bentley, J. Abdel-Khalik, I. Matthews, P.T. Clayton,
A.A. Morris, B.W. Bigger, C. Zerbinati, L. Tritapepe, L. Iuliano, Y. Wang,
W.J. Grifﬁths, Quantitative charge-tags for sterol and oxysterol analysis, Clin.
Chem. 61 (2015) 400e411.
[33] H. Roberg-Larsen, K. Lund, K.E. Seterdal, S. Solheim, T. Vehus, N. Solberg,
S. Krauss, E. Lundanes, S.R. Wilson, Mass spectrometric detection of 27-
hydroxycholesterol in breast cancer exosomes, J. Steroid Biochem. Mol. Biol.
169 (2017) 22e28.
[34] P.J. Crick, W.J. Grifﬁths, J. Zhang, M. Beibel, J. Abdel-Khalik, J. Kuhle,
A.W. Sailer, Y. Wang, Reduced plasma levels of 25-hydroxycholesterol and
increased cerebrospinal ﬂuid levels of bile acid precursors in multiple scle-
rosis patients, Mol. Neurobiol. 54 (2017) 8009e8020.
[35] A. Honda, T. Miyazaki, T. Ikegami, J. Iwamoto, T. Maeda, T. Hirayama, Y. Saito,
T. Teramoto, Y. Matsuzaki, Cholesterol 25-hydroxylation activity of CYP3A,
J. Lipid Res. 52 (2011) 1509e1516.
[36] E.A. Dennis, R.A. Deems, R. Harkewicz, O. Quehenberger, H.A. Brown,
S.B. Milne, D.S. Myers, C.K. Glass, G. Hardiman, D. Reichart, A.H. Merrill Jr.,
M.C. Sullards, E. Wang, R.C. Murphy, C.R. Raetz, T.A. Garrett, Z. Guan, A.C. Ryan,
D.W. Russell, J.G. McDonald, B.M. Thompson, W.A. Shaw, M. Sud, Y. Zhao,
S. Gupta, M.R. Maurya, E. Fahy, S. Subramaniam, A mouse macrophage lip-
idome, J. Biol. Chem. 285 (2010) 39976e39985.
[37] A. Goenka, A. Ghosh, S. Dixon, W.J. Grifﬁths, S.M. Hughes, W.G. Newman,
J. Urquhart, Y. Wang, R.F. Wynn, T. Hussell, S.A. Jones, P.D. Arkwright, Sus-
ceptibility to BCG abscess associated with deletion of two cholesterol meta-
bolism genes: lysosomal acid lipase and cholesterol 25-hydroxylase, in:
UKPIN Conference, Brighton, UK, 2017.
[38] R. Blassberg, J. Jacob, Lipid metabolism fattens up hedgehog signaling, BMC
Biol. 15 (2017) 95.
[39] R. Rohatgi, L. Milenkovic, R.B. Corcoran, M.P. Scott, Hedgehog signal trans-
duction by Smoothened: pharmacologic evidence for a 2-step activation
process, Proc. Natl. Acad. Sci. U. S. A. 106 (2009) 3196e3201.
[40] G. Luchetti, R. Sircar, J.H. Kong, S. Nachtergaele, A. Sagner, E.F. Byrne,
D.F. Covey, C. Siebold, R. Rohatgi, Cholesterol activates the G-protein coupled
receptor Smoothened to promote Hedgehog signaling, Elife 5 (2016), e20304.
[41] E.F. Byrne, R. Sircar, P.S. Miller, G. Hedger, G. Luchetti, S. Nachtergaele,
M.D. Tully, L. Mydock-McGrane, D.F. Covey, R.P. Rambo, M.S. Sansom,
S. Newstead, R. Rohatgi, Structural basis of Smoothened regulation by its
extracellular domains, Nature 535 (2016) 517e522.
[42] Y. Wang, W.J. Grifﬁths, Oxysterol Lipidomics in Mouse and Man, Keystone
Symposium, Lipidomics and Bioactive Lipids in Metabolism and Disease,
Granlibakken Tahoe, 2017. Tahoe City, California, USA.
[43] F. Mazzacuva, P. Mills, K. Mills, S. Camuzeaux, P. Gissen, E.R. Nicoli, C. Wassif,
D. Te Vruchte, F.D. Porter, M. Maekawa, N. Mano, T. Iida, F. Platt, P.T. Clayton,
Identiﬁcation of novel bile acids as biomarkers for the early diagnosis of
Niemann-Pick C disease, FEBS Lett. 590 (2016) 1651e1662.
[44] X. Jiang, R. Sidhu, L. Mydock-McGrane, F.F. Hsu, D.F. Covey, D.E. Scherrer,
B. Earley, S.E. Gale, N.Y. Farhat, F.D. Porter, D.J. Dietzen, J.J. Orsini, E. Berry-
Kravis, X. Zhang, J. Reunert, T. Marquardt, H. Runz, R. Giugliani, J.E. Schaffer,
D.S. Ory, Development of a bile acid-based newborn screen for Niemann-Pick
disease type C, Sci. Transl. Med. 8 (2016), 337ra363.
W.J. Grifﬁths, Y. Wang / Biochemical and Biophysical Research Communications xxx (2018) 1e66
Please cite this article in press as: W.J. Grifﬁths, Y. Wang, An update on oxysterol biochemistry: New discoveries in lipidomics, Biochemical and
Biophysical Research Communications (2018), https://doi.org/10.1016/j.bbrc.2018.02.019
